Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

Are Clinicians Still Feeling the Burn? A Look at HCP Mental Health and Well-Being

One of the most critical topics to address in health care today is the mental health and well-being of physicians and other healthcare professionals. The 2020 COVID-19 pandemic shined a...

Medscape Education

- PMLiVE

Eli Lilly and Alchemab Therapeutics enter ALS agreement worth up to $415m

The deal follows the companies’ earlier partnership to advance candidates for the neurodegenerative disease

- PMLiVE

Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis

More than 2.5 million people in Europe are affected by the inflammatory bowel disease

- PMLiVE

MHRA approves Bavarian Nordic’s chikungunya vaccine Vimkunya

Approximately 620,000 cases of the mosquito-borne viral disease were reported worldwide in 2024

- PMLiVE

Examining the health of the pharma: patient group relationship

Explore the positive aspects and areas for improvement in the relationship between patient advocacy groups and pharma companies when participating in research, educational initiatives and awareness campaigns.

Say Communications

- PMLiVE

AstraZeneca’s Calquence approved by EC for first-line mantle cell lymphoma use

The drug is now the only BTK inhibitor to be approved in the EU for first-line MCL

- PMLiVE

Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours

The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes

- PMLiVE

Alnylam’s RNAi therapeutic vutrisiran recommended by CHMP for rare heart disease

The committee has recommended the drug for both wild type and hereditary ATTR-CM

- PMLiVE

Live Q&A: Beyond NHS England – Navigating changes at NHSE and DHSC

What impact can we expect from the abolition of NHS England (NHSE) and changes at the Department of Health and Social Care (DHSC)? What do these changes mean for your...

Petauri Evidence

- PMLiVE

Johnson & Johnson’s Imaavy granted FDA approval for rare autoimmune disease gMG

Myasthenia gravis affects an estimated 700,000 people worldwide

- PMLiVE

NHS patients to access Theramex’s endometriosis pill following NICE recommendation

The once-a-day drug has been recommended for patients with a history of previous medical or surgical treatment

- PMLiVE

AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

Up to 262 million people worldwide are affected by the chronic respiratory disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links